Effects of omega-3 fatty acids on triglycerides and HDL sub-profiles in HIV-infected persons with hypertriglyceridemia.

AIDS research and human retroviruses

PubMedID: 24988179

Paranandi A, Asztalos BF, Mangili A, Kuvin JT, Gerrior J, Sheehan H, Tang AM, Skinner S, Wanke C. Effects of omega-3 fatty acids on triglycerides and HDL sub-profiles in HIV-infected persons with hypertriglyceridemia. AIDS Res Hum Retroviruses. 2014;.
Abstract Objective: Hypertriglyceridemia and low HDL-cholesterol (HDL-C) have been identified as independent risk factors for accelerated cardiovascular disease in the general population, and may contribute to a presumed accelerated risk for cardiovascular disease in HIV-infected individuals. We evaluated the effect of omega-3 fatty acid treatment on triglycerides, LDL-C, HDL-C and HDL subpopulations. Methods: Forty-one HIV seropositive subjects with hypertriglyceridemia (=150 mg/dL) on active antiretroviral therapy were enrolled in this placebo-controlled, double-blind, randomized, crossover trial comparing the effects of omega-3 fatty acid treatment (1.9g EPA and 1.5g DHA) on triglycerides, LDL-C, HDL-C, and HDL subpopulations. Independent sample t-test was used to assess the study start to post-treatment change for all components. Results: After omega-3 fatty acid treatment, triglyceride levels decreased 63.2 ± 86.9 mg/dL (p<0.001). No significant changes in total cholesterol, LDL-C, or HDL-C were found. Within HDL subpopulations, significant changes were seen in the most atheroprotective HDL particles, a-1, which increased by 2.5 ± 5.6 mg/dL (p<0.05), and prea-1, which increased by 0.6 ± 1.0 mg/dL (p<0.001). Prea-3, a presumably atherogenic HDL particle decreased 0.5 ± 0.9 mg/dL (p<0.01). Conclusion: Omega-3 fatty acid treatment significantly lowered triglycerides in HIV-positive patients with moderate hypertriglyceridemia. While no study-wide improvements in LDL-C or HDL-C were detected, the HDL subpopulation profile changed in a beneficial way suggesting more cardio-protection after treatment. The trial was registered at clinicaltrials.gov as NCT00795717.